



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/500,838	02/02/2005	Daniel W. Chan	56792(71699)	1171
49383	7590	07/07/2010	EXAMINER	
EDWARDS ANGELI, PALMER & DODGE LLP			HARRIS, ALANA M	
P.O. BOX 55874			ART UNIT	PAPER NUMBER
BOSTON, MA 02205			1643	
MAIL DATE		DELIVERY MODE		
07/07/2010		PAPER		

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b> 10/500,838	<b>Applicant(s)</b> CHAN ET AL.
	<b>Examiner</b> Alana M. Harris, Ph.D.	<b>Art Unit</b> 1643

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If no period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED. (35 U.S.C. § 133).

Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

1) Responsive to communication(s) filed on 31 March 2010.

2a) This action is FINAL.      2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

4) Claim(s) 3-5,9-12,35,39,40 and 62 is/are pending in the application.

4a) Of the above claim(s) 40 is/are withdrawn from consideration.

5) Claim(s) \_\_\_\_\_ is/are allowed.

6) Claim(s) 3-5, 9-12, 35, 39 and 62 is/are rejected.

7) Claim(s) \_\_\_\_\_ is/are objected to.

8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All    b) Some \* c) None of:  
 1. Certified copies of the priority documents have been received.  
 2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

1) Notice of References Cited (PTO-892)  
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  
 3) Information Disclosure Statement(s) (PTO/SB/06)  
Paper No(s)/Mail Date \_\_\_\_\_

4) Interview Summary (PTO-413)  
Paper No(s)/Mail Date: \_\_\_\_\_

5) Notice of Informal Patent Application  
 6) Other: \_\_\_\_\_

## **DETAILED ACTION**

### ***Response to Arguments***

1. Claims 3-5, 9-12, 34, 39, 40 and 62 are pending.

Claim 40, drawn to non-elected inventions are withdrawn from examination.

Claims 3-5, 9-12, 34, 39 and 62 are examined on the merits.

### ***Claim Objections***

2. Claim 3 is objected to because of the following informality: it is not clear if Applicants have misnumbered the markers listed in the claim. Moreover, it is not clear if the listed as Marker VII on line 10 of the claim should be listed as Marker VI. Clarification is required.

### ***Maintained Grounds of Rejection***

#### ***Claim Rejections - 35 USC § 112***

3. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

4. The **NEW MATTER REJECTION** of claims 3-5, 9-12, 34, 39 and 62 under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement is maintained.

Applicants continue to assert the amendment submitted February 11, 2008 made to claim 3 to recite "wherein an increase in the levels of one or more of Markers II and III, or a decrease in the levels of one or more of Markers I, IV, V or VII is indicative that the subject has ovarian cancer." is supported by the specification, see Remarks submitted March 31, 2010. In addition to the previously cited Example 1 found on page 47, lines 28-31 wherein it is cited

"...peaks at 9.2kD [Marker II], 19.8kD [Marker III], and 60kD showed higher expression levels on average among the specimens from the cancer patients compared to the controls while the remaining peaks demonstrated the inverse expression pattern."

Applicants point out page 42 of the specification, where 80 specimens (42 from ovarian specimens and 38 no known cancer specimens) were assayed. It is clear from that passage ovarian samples are assayed, however Example 1 is not as clear. Applicants' claims read on a specific cancer, ovarian cancer, while the support Applicants point out broadly references cancer. Hence, it is not clear if the markers cited in lines 26-31 on page 47 correspond for example to ovarian cancer, prostate cancer or bladder cancer.

Applicants' aver Example 1 clearly indicates higher expression levels of Marker II (9.2kD), Marker III (19.8kD) and 60kD among specimens from the cancer patients, however the particular type of cancer the patients have has not been clearly denoted. As noted in the Request for Continued Examination mailed December 31, 2009 the corresponding figure and description, Figure 2B and figure description found on page 11, lines 25-29 and does not see support

for the cited amendment. The specification at page 47 notes having three peaks with higher expression and not just one Marker or two as set forth in the claims and the citation also includes a third marker, 60kD, which is not of record in the claims.

The Examiner continues to not find support for the amendment to claim 3 and the rejection is maintained. Applicants are requested to list the page and line numbers within the disclosure that are commensurate with the amendment or delete the new matter.

***Conclusion***

5. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

6. Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Alana M. Harris, Ph.D. whose telephone number is (571)272-0831. The Examiner works a *flexible schedule*, however she can normally be reached between the hours of 8 am to 8 pm, with alternate Fridays off.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Larry R. Helms, Ph.D. can be reached on (571) 272-0832. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Alana M. Harris, Ph.D.  
22 June 2010

Application/Control Number: 10/500,838

Page 6

Art Unit: 1643

/Alana M. Harris, Ph.D./

Primary Examiner, Art Unit 1643